Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Rozzano
Clinical trial register · Italy

Clinical Trials in Rozzano, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 73 Roma 52 Rozzano 26 Florence 24 Ancona 24
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Istituto Clinico Humanitas40 AstraZeneca40 Merck Sharp & Dohme LLC27 Novartis Pharmaceuticals26 AbbVie21 Clear sponsor filter
Site location
Milan73 Roma52 Rozzano26 Florence24 Ancona24
All 66 locations
Target enrolment
to

Trials with a site in Rozzano

26 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Ancona, Cona, Milan, Rozzano
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Rozzano, Verona
2026-01-13
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Cona, Genova, Milan, Rozzano, Pisa, Roma
2025-05-30
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Ancona, Caserta, Grosseto, Milan, Rozzano, Perugia, Pordenone, Salerno
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa
2025-01-31
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Ancona, Brescia, Monza, Milan, Rozzano, Verona
2024-12-17
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Ancona, Milan, Rozzano, Modena, Palermo, Pavia, Roma, Verona
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alessandria, Ancona, Genova, Milan, Rozzano, Pescara, Pisa, Pavia
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Ancona, Milan, Rozzano
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Milan, Rozzano, Modena, Roma, Siena
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Milan, Rozzano
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Brescia, Rozzano
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Bari, Rozzano, Roma, Orbassano
2022-12-06
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Milan, Rozzano, Torino
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Bari, Bergamo, Bologna, Florence, Genova, Milan, Rozzano, Palermo
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 1
137
Milan, Rozzano
2021-10-21
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Milan, Rozzano, Modena, Aviano, Siena, Naples
2019-10-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bologna, Milan, Roma, Rozzano
2019-09-18
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Bergamo, Milan, Rozzano
2019-06-26
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Ancona, Bergamo, Bologna, Misterbianco, Milan, Rozzano, Palermo, Aviano
2018-12-07
Active, closed
Novartis Pharmaceuticals
Phase 1
105
Ancona, Milan, Rozzano
2018-01-29
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Bergamo, Bologna, Brescia, Meldola, Monza, Milan, Rozzano, Modena
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Bologna, Monza, Milan, Rozzano, Roma
2015-11-02
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Ancona, Bari, Bologna, Brescia, San Giovanni Rotondo, Florence, Milan, Rozzano
2015-03-05
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/rozzano

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies with a site in Rozzano that also match the filters currently applied.

How many clinical trials are recruiting in Rozzano?

7 of the 26 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Rozzano), 26 studies
PhaseStudiesRecruitingShare
Phase 311342.3%
Phase 15019.2%
Phase 25219.2%
Phase 1/23211.5%
Phase 4207.7%

Most active sponsors

Lead sponsors with the most studies (Rozzano)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals267
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.